Racial Differences in Heart Failure Therapeutics

Heart Failure Clinics

Volumn 6, Issue 1, 2010, Pages 65-74

  Ishizawar, David ^a   Yancy, Clyde ^b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

African Americans; Heart failure; Isosorbide dinitrate and hydralazine; Nitric oxide; Pharmacogenomics; Race; Renin angiotensin aldosterone system

Indexed keywords

ALDOSTERONE ANTAGONIST; ALDOSTERONE SYNTHASE; ALPHA ADRENERGIC RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CANDESARTAN; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; G PROTEIN COUPLED RECEPTOR KINASE 5; GUANINE NUCLEOTIDE BINDING PROTEIN BETA SUBUNIT; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; METOPROLOL; NEUROHORMONE; NITRIC OXIDE; SPIRONOLACTONE; VASODILATOR AGENT;

AFRICAN AMERICAN; AMINO ACID SUBSTITUTION; DEMOGRAPHY; DESENSITIZATION; DISEASE COURSE; DNA POLYMORPHISM; DRUG EFFICACY; ETHNIC DIFFERENCE; EVENT FREE SURVIVAL; GENE FREQUENCY; GENETIC RISK; GENOTYPE; HEALTH CARE QUALITY; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HOMOZYGOSITY; HUMAN; MORBIDITY; MORTALITY; PHARMACOGENOMICS; PHENOTYPE; PREVALENCE; QUALITY OF LIFE; RACE DIFFERENCE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SOCIOECONOMICS; SURVIVAL RATE;

ADRENERGIC BETA-ANTAGONISTS; AFRICAN AMERICANS; ANTIHYPERTENSIVE AGENTS; DRUG COMBINATIONS; HEART FAILURE; HUMANS; HYDRALAZINE; ISOSORBIDE DINITRATE; NITRIC OXIDE; NITRIC OXIDE DONORS; PHENOTYPE; POLYMORPHISM, GENETIC; RENIN-ANGIOTENSIN SYSTEM; RISK ASSESSMENT; UNITED STATES;

EID: 70450185104     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2009.08.006     Document Type: Review

References (62)

1. 2009 American Heart Association. Statistical fact sheet. Available at:. www.americanheart.org Accessed May 5, 2009
2. Dries D.L., Exner D.V., Gersh B.J., et al. Racial differences in the outcome of left ventricular dysfunction. N Engl J Med 340 (1999) 609-616
3. Exner D.V., Dries D.L., Domanski M.J., et al. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 344 (2001) 1351-1357
4. Taylor A.L., Ziesche S., Yancy C., et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 351 (2004) 2049-2057
5. Kamath S.A., Drazner M.H., Wynne J., et al. Characteristics and outcomes in African American patients with decompensated heart failure. Arch Intern Med 168 (2008) 1152-1158
6. Yancy C.W., Abraham W.T., Albert N.M., et al. Quality of care of and outcomes for African Americans hospitalized with heart failure. J Am Coll Cardiol 51 (2008) 1675-1684
7. Bibbins-Domingo K., Pletcher M.J., Lin F., et al. Racial differences in incident heart failure among young adults. N Engl J Med 360 (2009) 1179-1180
8. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. The SOLVD investigators. N Engl J Med 325 (1991) 293-302
9. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD investigators. N Engl J Med 327 (1992) 685-691 [Erratum, N Engl J Med 1992;327:1768]
10. Cohn J.N., Archibald D.G., Ziesche S., et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study (V-HeFT). N Engl J Med 314 (1986) 1547-1552
11. Cohn J.N., Johnson G., Ziesche S., et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325 (1991) 303-310
12. Carson P., Ziesche S., Johnson G., et al. Racial differences in response to therapy for heart failure: analysis of the Vasodilator-Heart Failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail 5 (1999) 178-187
13. Stein C.M., Lang C.C., Nelson R., et al. Vasodilation in black Americans: attenuated nitric oxide-mediated responses. Clin Pharmacol Ther 62 (1997) 436-443
14. Cardillo C., Kilcoyne C.M., Cannon III R.O., et al. Racial differences in nitric oxide-mediated vasodilator response to mental stress in the forearm circulation. Hypertension 31 (1998) 1235-1239
15. Kahn D.F., Duffy S.J., Tomasian D., et al. Effects of black race on forearm resistance vessel function. Hypertension 40 (2002) 195-201
16. Taylor A.L. The African-American Heart Failure Trial (A-HeFT): rationale and methodology. J Card Fail 9 Suppl (2003) S216-S219
17. The Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 344 (2001) 1659-1667
18. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353 (1999) 2001-2007
19. Packer M., Coats A.J.S., Fowler M.B., et al. Effect of carvedilol on survival in severe chronic heart disease. N Engl J Med 344 (2001) 1651-1658
20. CIBIS-II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomized trial. Lancet 353 (1999) 9-13
21. Eichhorn E.J., Domanski M.J., Adams K., et al. Effect of beta-blockade on mortality in African-Americans: the Beta-blocker Evaluation of Survival Trial. Circulation 102 Suppl II (2000) 778 II
22. Eichhorn E.J., Domanski M.J., Adams K., et al. Hemodynamic, myocardial functional and neurohormonal responses to beta-blockade in black vs non-black patients in BEST. Circulation 102 Suppl II (2000) 778 II
23. Andreka P., Aiyar N., Olson L.C., et al. Bucindolol displays intrinsic sympathomimetic activity in human myocardium. Circulation 105 (2002) 2429-2434
24. Carson P., Fowler M.B., Mohacsi P., et al. Effect of carvedilol in black patients with severe chronic heart failure: results of the COPERNICUS study. Circulation 104 Suppl II (2001) II-754
25. Yancy C.W., Fowler M.B., Colucci W.S., et al. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med 344 (2001) 1358-1365
26. Goldstein S., Deedwania P., Gottlieb S., et al. Metoprolol CR/XL in black patients with heart failure (from the Metoprolol CR/XL Randomized Intervention Trial in Chronic Heart Failure). Am J Cardiol 92 (2003) 478-480
27. Shekelle P.G., Rich M.W., Morton S.C., et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status. A meta-analysis of major clinical trials. J Am Coll Cardiol 41 (2003) 1529-1538
28. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341 (1999) 709-717
29. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 (2003) 1309-1321
30. Pfeffer M.A., Swedberg K., Granger G.B., et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362 (2003) 759-766
31. Cohn J.N., and Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345 (2001) 1667-1675
32. International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature 409 (2001) 860-921
33. International Human Genome Sequencing Consortium. A physical map of the human genome. Nature 409 (2001) 934-941
34. Venter J.C., Adams M.D., Myers E.W., et al. The sequence of the human genome. Science 291 (2001) 1304-1351 [Erratum, Science 2001;292: p. 1838]
35. International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature 431 (2004) 931-945
36. Rigat B., Hubert C., Alhenc-Gelas F., et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 86 (1990) 1343-1346
37. Tiret L., Rigat B., Visvikis S., et al. Evidence from combined segregation and linkage analysis that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet 51 (1992) 197-205
38. Danser A.H., Deinum J., Osterop A.P., et al. Angiotensin I to angiotensin II conversion in the human forearm and leg. Effect of the angiotensin converting enzyme gene insertion/deletion polymorphism. J Hypertens 17 (1999) 1867-1872
39. Andersson B., and Sylven C. The DD genotype of the angiotensin-converting enzyme gene is associated with increased mortality in idiopathic heart failure. J Am Coll Cardiol 28 (1996) 162-167
40. Cicoira M., Zanolla L., Rossi A., et al. Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype. J Am Coll Cardiol 37 (2001) 1808-1821
41. McNamara D.M., Holubkov R., Janosko K., et al. Pharmacogenetic interactions between beta-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. Circulation 103 (2001) 1644-1648
42. McNamara D.M., Holubkov R., Postava L., et al. Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. J Am Coll Cardiol 44 (2004) 2019-2026
43. Tang W.H.W., Vagelos R.H., Yee Y.G., et al. Impact of angiotensin-converting enzyme gene polymorphism on neurohormonal responses to high- versus low-dose enalapril in advanced heart failure. Am Heart J 148 (2004) 889-894
44. Moore J.D., Mason D.A., Green S.A., et al. Racial differences in the frequencies of cardiac beta1-adrenergic receptor polymorphisms: analysis of c145A>G and c1165G>C. Hum Mutat 14 (1999) 271
45. Xie H.G., Dishy V., Sofowora G., et al. Arg389Gly beta1-adrenoceptor polymorphism varies in frequency among different ethnic groups but does not alter response in vivo. Pharmacogenetics 11 (2001) 191-197
46. Liggett S.B., Mialet-Perez J., Thaneemit-Chen S., et al. A polymorphism within a conserved beta1-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A 103 (2006) 11288-11293
47. White H.L., de Boer R.A., Maqbool A., et al. An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study. Eur J Heart Fail 5 (2003) 463-468
48. Liggett S.B., Cresci S., Kelly R.J., et al. A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med 14 (2008) 510-517
49. McNamara D.M., Tam S.W., Sabolinski M.L., et al. Aldosterone synthase promoter polymorphism predicts outcome in African Americans with heart failure. Results from the A-HeFT trial. J Am Coll Cardiol 48 (2006) 1277-1282
50. McNamara D.M., Tam S.W., Sabolinski M.L., et al. Endothelial nitric oxide synthase (NOS3) polymorphisms in African Americans with heart failure: results from the A-HeFT trial. J Card Fail 15 (2009) 191-198
51. White P.C., and Slutsker L. Haplotype analysis of CYP11B2. Endocr Res 21 (1995) 437-442
52. Brand E., Chatelain N., Mulatero P., et al. Structural analysis and evaluation of the aldosterone synthase gene in hypertension. Hypertension 32 (1998) 198-204
53. Komiya I., Yamada T., Takara M., et al. Lys173Arg and - 344T/C variants of CYP11B2 in Japanese patients with low-renin hypertension. Hypertension 35 (2000) 699-703
54. Duffy S.J., Biegelsen E.S., Eberhardt R.T., et al. Low-renin hypertension with relative aldosterone excess is associated with impaired NO-mediated vasodilation. Hypertension 46 (2005) 707-713
55. Schunkert H., Hense H.W., Döring A., et al. Association between a polymorphism in the G protein β3 subunit gene and lower renin and elevated diastolic blood pressure levels. Hypertension 32 (1998) 510-513
56. G protein beta 3 subunit (GNB3) genotype predicts enhanced benefit of fixed-dose isosorbide dinitrate and hydralazine-results of the A-HeFT trial. Circulation 114 Suppl 18 (2006) 442 II
57. Dong Y., Zhu H., Sagnella G.A., et al. Association between the C285T polymorphism of the G protein β3-subunit gene and hypertension in blacks. Hypertension 34 (1999) 1193-1196
58. Siffert W., Rosskopf D., Siffert G., et al. Association of a human G-protein β3 subunit variant with hypertension. Nat Genet 18 (1998) 45-48
59. Beige J., Hohenbleicher H., Distler A., et al. G-protein β3 subunit C825T variant and ambulatory blood pressure in essential hypertension. Hypertension 33 (1999) 1049-1051
60. Benjafield A.V., Jeyasingam C.L., Nyholt D.R., et al. G-protein β3 subunit gene (GNB3) variant in causation of essential hypertension. Hypertension 32 (1998) 1094-1097
61. Tanus-Santos J.E., Desai M., and Flockhart D.A. Effects of ethnicity on the distribution of clinically relevant endothelial nitric oxide variants. Pharmacogenetics 11 (2001) 719-725
62. Zhu H., Wang X., Dong Y., et al. Influence of the eNOS gene on development of blood pressure and left ventricular mss: longitudinal findings in multiethnic youth. Pharmacogenet Genomics 15 (2005) 669-675